Pfizer subsidiary dumps direct distribution model to return to CSO wholesale deliveries
Upjohn Australia, a subsidiary of Pfizer, has announced that it will distribute its medicines through Community Service Obligation (CSO) pharmaceutical distributors from February 2020.
Upjohn announced the decision today by signing a contract with Symbion, and expects to finalise negotiations with other wholesalers shortly.
Gareth Richmond, Upjohn general manager Australia and New Zealand, said the repositioning of the medicine distribution was a commercial decision to “ensure the business is in the best position for growth going forward, and to ensure patients continue to have access to its medicines”.
Upjohn is an off-patent branded and established medicines business, which in Australia markets 18 off-patent medicines and globally, markets 20 off-patent brands.
“This is an important step for Upjohn in Australia that will enable us to establish a distribution model independent of Pfizer Australia and to ensure patients continue to have access to our medicines,” Mr Richmond said in a release.
Pfizer Australia’s finance director Bradley Apps said the Upjohn decision would not impact the remaining BioPharma business of Pfizer in Australia.
“Australians will have continued access to our innovative, generic and biosimilar medicines. We will continue to offer next business day delivery, through Pfizer Direct, to more than 5,600 pharmacies in Australia, which is virtually all pharmacies in Australia”, he said.